MS Patient Treatment Preferences Diverge From Payers, Physicians
Executive Summary
Survey finds patient assign greatest value to a drug’s effect on multiple sclerosis symptoms.
You may also be interested in...
Tysabri Liability: Biogen's Dialogue With FDA Helps Get Suit Tossed
Judge finds Tysabri label warnings about brain infection were adequate and that there is 'clear evidence' FDA would not have approved a labeling change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.